Literature DB >> 15790362

The stages of type 1A diabetes: 2005.

Roberto Gianani1, George S Eisenbarth.   

Abstract

Type 1A diabetes is a chronic autoimmune disease usually preceded by a long prodrome during which autoantibodies to islet autoantigens are present. These antibodies are directed to a variety of antigens, but the best characterized are glutamic acid decarboxylase-65, insulinoma-associated antigen-2, and insulin. We hypothesize that the natural history of type 1A diabetes can be represented by several stages, starting from genetic susceptibility and ending in complete beta-cell destruction and overt diabetes. Type 1A diabetes probably results from a balance between genetic susceptibility and environmental influences. In both humans and animal models, the major determinants of the disease are genes within the major histocompatibility complex. The next best-characterized susceptibility locus is the insulin gene, the variable nucleotide tandem repeat locus. This gene affects the expression of insulin in the thymus and thus may play a role in the modulation of tolerance to this molecule. In a subset of genetically susceptible individuals, the activation of autoimmunity may be triggered by environmental factors such as viruses and/or diet. However, no conclusive association has been established between type 1A diabetes and specific environmental triggers. In this review, we provide evidence that insulin has a fundamental role in anti-islet autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15790362     DOI: 10.1111/j.0105-2896.2005.00248.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  34 in total

Review 1.  Genetic epidemiology of type 1 diabetes.

Authors:  Andrew D Paterson
Journal:  Curr Diab Rep       Date:  2006-04       Impact factor: 4.810

2.  Immunosuppression in islet transplantation.

Authors:  Tom Van Belle; Matthias von Herrath
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

3.  Rotavirus-specific T cell responses and cytokine mRNA expression in children with diabetes-associated autoantibodies and type 1 diabetes.

Authors:  M Mäkelä; V Oling; J Marttila; M Waris; M Knip; O Simell; J Ilonen
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

Review 4.  Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes.

Authors:  Frank Waldron-Lynch; Kevan C Herold
Journal:  Nat Rev Drug Discov       Date:  2011-06       Impact factor: 84.694

Review 5.  Bioengineered stem cells as an alternative for islet cell transplantation.

Authors:  Sarah J Moore; Boris L Gala-Lopez; Andrew R Pepper; Rena L Pawlick; Am James Shapiro
Journal:  World J Transplant       Date:  2015-03-24

6.  Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes.

Authors:  Aimon K Alkanani; Naoko Hara; Peter A Gottlieb; Diana Ir; Charles E Robertson; Brandie D Wagner; Daniel N Frank; Danny Zipris
Journal:  Diabetes       Date:  2015-06-11       Impact factor: 9.461

7.  α1-Antitrypsin therapy downregulates toll-like receptor-induced IL-1β responses in monocytes and myeloid dendritic cells and may improve islet function in recently diagnosed patients with type 1 diabetes.

Authors:  Peter A Gottlieb; Aimon K Alkanani; Aaron W Michels; Eli C Lewis; Leland Shapiro; Charles A Dinarello; Danny Zipris
Journal:  J Clin Endocrinol Metab       Date:  2014-02-14       Impact factor: 5.958

Review 8.  The Role of the Intestinal Microbiome in Type 1 Diabetes Pathogenesis.

Authors:  James C Needell; Danny Zipris
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

9.  Quantification and three-dimensional imaging of the insulitis-induced destruction of beta-cells in murine type 1 diabetes.

Authors:  Tomas Alanentalo; Andreas Hörnblad; Sofia Mayans; Anna Karin Nilsson; James Sharpe; Asa Larefalk; Ulf Ahlgren; Dan Holmberg
Journal:  Diabetes       Date:  2010-04-14       Impact factor: 9.461

Review 10.  New potential treatments for protection of pancreatic B-cell function in Type 1 diabetes.

Authors:  S Cernea; P Pozzilli
Journal:  Diabet Med       Date:  2008-11       Impact factor: 4.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.